ANIP
ANI Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
5.47 / 10
Netural
Analyst coverage is limited but strongly bullish, with 100% of ratings classified as 'Strong Buy' from one analyst. Money flow analysis shows a good score of 7.7/10; small and medium inflows are positive, while large and extra-large flows are negative, indicating possible institutional profit-taking. The sentiment score of 5.47 remains neutral, reflecting a balanced yet not overwhelmingly confident market outlook.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-16
InstitutionGuggenheim
Times predicted6
Historical Win Rate33.3%
What is the analyst consensus for ANIP?
- ANIP holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.47/10 (Netural).
